ArticleAnnals of nuclear medicine2026
Quantitative and comparative assessment of Tc-99 m MIBI imaging in parathyroid adenomas: associations with biochemical, morphological, and histopathological.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the relationships between Tc-99 m methoxyisobutylisonitrile (MIBI) SPECT/CT-derived SUVmax values and adenoma volume, histopathological characteristics, and biochemical parameters in patients with primary hyperparathyroidism (PHPT), and to compare the localization performance of ultrasonography (USG), planar scintigraphy, pinhole imaging, and SPECT/CT.
methodsSixty patients with histopathologically confirmed solitary parathyroid adenomas who underwent preoperative Tc-99 m MIBI scintigraphy and subsequent surgery were retrospectively included. SUVmax values were obtained from quantitative SPECT/CT images using manually defined volumetric regions of interest. Associations between SUVmax and continuous clinicopathological variables were evaluated using Spearman correlation analysis, while comparisons among predominant cell-type groups were performed using the Kruskal-Wallis test. Detection rates of the imaging modalities were compared using Cochran's Q test.
resultsSUVmax demonstrated significant positive correlations with adenoma volume (ρ = 0.523, p < 0.001), lesion diameter (ρ = 0.459, p < 0.001), and serum parathyroid hormone levels (ρ = 0.360, p = 0.005). Adenoma volume was also positively correlated with serum PTH (ρ = 0.356, p = 0.005) and calcium levels (ρ = 0.407, p = 0.001). Median SUVmax was numerically highest in oxyphil-predominant adenomas; however, the difference among cellular subtypes was not statistically significant (p = 0.441). When positive and suspicious findings were considered together, lesion detection rates were 88.3% for USG, 96.7% for planar scintigraphy, 95.0% for pinhole imaging, and 98.3% for SPECT/CT, without a statistically significant difference among modalities (Cochran's Q = 7.545, p = 0.056). All lesions that were negative on USG were localized by planar and pinhole imaging, while SPECT/CT identified six of seven such lesions.
conclusionTc-99 m MIBI SPECT/CT-derived SUVmax was significantly associated with adenoma volume in patients with PHPT. Oxyphil-predominant adenomas showed numerically higher SUVmax values, although differences among cellular subtypes were not statistically significant. Scintigraphic techniques provided complementary localization information in lesions not identified by ultrasonography. The clinical utility of quantitative SPECT/CT and its potential relationships with histopathological characteristics require further validation in larger prospective studies.
Indexed as
Identifiers
42821057What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.